Akari Therapeutics Plc (AKTX)

$1.91

+0.27

(+16.82%)▲

Market is closed - opens 7 PM, 23 May 2024

Insights on Akari Therapeutics Plc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 118.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 328.1%

Performance

  • $1.58
    $2.04
    $1.91
    downward going graph

    17.28%

    Downside

    Day's Volatility :22.55%

    Upside

    6.37%

    downward going graph
  • $1.08
    $5.50
    $1.91
    downward going graph

    43.46%

    Downside

    52 Weeks Volatility :80.36%

    Upside

    65.27%

    downward going graph

Returns

PeriodAkari Therapeutics PlcIndex (Russel 2000)
3 Months
-27.01%
0.0%
6 Months
-45.5%
0.0%
1 Year
-59.73%
0.0%
3 Years
-95.48%
-20.1%

Highlights

Market Capitalization
12.1M
Book Value
- $0.44
Earnings Per Share (EPS)
-2.05
PEG Ratio
0.0
Wall Street Target Price
80.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-210.95%
Return On Equity TTM
-1281.43%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-18.2M
Diluted Eps TTM
-2.05
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Akari Therapeutics Plc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 4088.48%

Current $1.91
Target $80.00

Technicals Summary

Sell

Neutral

Buy

Akari Therapeutics Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Akari Therapeutics Plc
Akari Therapeutics Plc
38.56%
-45.5%
-59.73%
-95.48%
-96.61%
Moderna, Inc.
Moderna, Inc.
37.56%
83.82%
13.37%
-12.47%
553.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
10.42%
24.29%
32.26%
98.6%
210.52%
Novo Nordisk A/s
Novo Nordisk A/s
7.9%
30.89%
58.53%
230.87%
458.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.52%
25.13%
30.01%
109.26%
156.43%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Akari Therapeutics Plc
Akari Therapeutics Plc
NA
NA
0.0
0.0
-12.81
-2.11
NA
-0.44
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.46
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.16
29.16
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.83
45.83
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.9
28.9
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Akari Therapeutics Plc
Akari Therapeutics Plc
Buy
$12.1M
-96.61%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.0B
553.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.8B
210.52%
29.16
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$592.1B
458.51%
45.83
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.1B
156.43%
28.9
39.46%

Institutional Holdings

  • Omnia Family Wealth, LLC

    1.55%

  • HPM Partners LLC

    0.42%

  • Renaissance Technologies Corp

    0.18%

Company Information

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Organization
Akari Therapeutics Plc
Employees
9
CEO
Ms. Rachelle Suzanne Jacques
Industry
Health Technology

Discover More

FAQs